amyloid beta 1-6-CMVWT

A preclinical **virus-like particle therapeutic vaccine** candidate for **Alzheimer's disease** consisting of the N-terminal amyloid beta peptide **Aβ1-6** chemically conjugated to **wild-type cucumber mosaic virus-like particles** lacking the inserted tetanus toxoid helper epitope present in CMVTT constructs. The intended mechanism is active immunization against **amyloid beta**, aiming to induce anti-Aβ IgG antibodies that recognize aggregated human **Aβ1-42** plaques. In the cited work, amyloid beta 1-6-CMVWT was used as the **wild-type CMV VLP comparator/control vaccine** versus Aβ1-6-CMVTT, and was described as analogous in concept to the VLP-based CAD106 approach because both display the same Aβ1-6 epitope. Development appears limited to **preclinical immunogenicity studies in mice**, with no clinical development for this exact CMVWT construct identified in the provided material.

Other names

Aβ1-6-CMVWTAbeta-CMVWT